Esperion Reports Record Q4 2025 Earnings and Strategic Acquisition
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1 hour ago
0mins
Should l Buy ESPR?
Source: seekingalpha
- Strong Financial Performance: Esperion's Q4 total revenue reached $168.4 million, marking a 144% year-over-year increase, with U.S. net product revenue at $43.7 million, reflecting approximately a 38% growth compared to the same period in 2024, showcasing robust market execution and product demand.
- Strategic Acquisition Progress: The announced acquisition of Corstasis Therapeutics is expected to create powerful synergies for its global bempedoic acid portfolio and Enbumyst product line, targeting a $4 billion U.S. outpatient heart failure market, thereby further solidifying its market position.
- Accelerated International Expansion: Daiichi Sankyo Europe reported a 51% increase in royalty revenue in Q4, successfully entering 30 countries and launching in France, indicating the company's capability and growth potential in global markets.
- Optimistic Future Outlook: The company projects 2026 operating expenses to range between $225 million and $255 million, including $15 million in non-cash stock compensation expenses, with management expressing confidence in future market positioning and product launches, particularly in the upcoming U.S. dyslipidemia guidelines.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ESPR?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on ESPR
Wall Street analysts forecast ESPR stock price to rise
5 Analyst Rating
4 Buy
0 Hold
1 Sell
Moderate Buy
Current: 3.040
Low
1.72
Averages
7.94
High
16.00
Current: 3.040
Low
1.72
Averages
7.94
High
16.00
About ESPR
Esperion Therapeutics, Inc. is a commercial stage biopharmaceutical company. The Company is focused on developing and commercializing oral, once-daily, non-statin medicines for patients who are at risk for cardiovascular disease (CVD) and are struggling with elevated low-density lipoprotein cholesterol (LDL-C). Its products include NEXLETOL, NEXLIZET, NILEMDO and NUSTENDI. Its NEXLETOL and NEXLIZET (bempedoic acid and ezetimibe) tablets are oral, once-daily, non-statin medicines to lower the risk of myocardial infarction and coronary revascularization in adults with primary hyperlipidemia. Its NEXLETOL is an ATP Citrate Lyase (ACLY), inhibitor that lowers LDL-C and cardiovascular risk by reducing cholesterol biosynthesis and up-regulating the LDL receptors. Its NUSTENDI contains bempedoic acid and ezetimibe and lowers elevated LDL-C through complementary mechanisms of action by inhibiting cholesterol synthesis in the liver and absorption in the intestine.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Esperion Therapeutics Set to Announce Q4 Earnings on March 10
- Earnings Announcement: Esperion Therapeutics is set to release its Q4 earnings on March 10 before market open, with a consensus EPS estimate of $0.28, reflecting a substantial year-over-year increase of 354.5%, indicating a significant improvement in profitability that could positively impact stock prices.
- Strong Revenue Expectations: The anticipated revenue for Q4 is $166.12 million, representing a 140.4% year-over-year growth, which highlights the company's enhanced competitiveness in the market and may attract increased investor interest.
- Historical Performance Review: Over the past year, Esperion has exceeded EPS estimates 75% of the time and revenue estimates 100% of the time, demonstrating a consistent performance that bolsters market confidence in its future financial health.
- M&A Activity: Esperion plans to acquire Corstasis for an upfront payment of $75 million, a strategic move that not only expands its product line but also has the potential to enhance market share through resource integration, further solidifying its position in the biopharmaceutical sector.
See More
Esperion Reports Record Q4 2025 Earnings and Strategic Acquisition
- Strong Financial Performance: Esperion's Q4 total revenue reached $168.4 million, marking a 144% year-over-year increase, with U.S. net product revenue at $43.7 million, reflecting approximately a 38% growth compared to the same period in 2024, showcasing robust market execution and product demand.
- Strategic Acquisition Progress: The announced acquisition of Corstasis Therapeutics is expected to create powerful synergies for its global bempedoic acid portfolio and Enbumyst product line, targeting a $4 billion U.S. outpatient heart failure market, thereby further solidifying its market position.
- Accelerated International Expansion: Daiichi Sankyo Europe reported a 51% increase in royalty revenue in Q4, successfully entering 30 countries and launching in France, indicating the company's capability and growth potential in global markets.
- Optimistic Future Outlook: The company projects 2026 operating expenses to range between $225 million and $255 million, including $15 million in non-cash stock compensation expenses, with management expressing confidence in future market positioning and product launches, particularly in the upcoming U.S. dyslipidemia guidelines.
See More
Esperion Reports 21% Revenue Growth in FY25, Acquires Corstasis Therapeutics
- Strong Financial Performance: Esperion reported total revenue of $403.1 million for FY25, reflecting a 21% year-over-year increase, with U.S. net product revenue reaching $159.6 million, up 38%, indicating robust growth in its cardiovascular franchise.
- Strategic Acquisition: The company announced the acquisition of Corstasis Therapeutics to accelerate growth and expand its cardiovascular portfolio, particularly with Enbumyst™ nasal diuretic, which targets a market of over 6.7 million U.S. heart failure patients, enhancing market share.
- Prescription Growth: In Q4 2025, retail prescription equivalents grew by 34% year-over-year and 11.3% quarter-over-quarter, reflecting ongoing improvements in market penetration and brand recognition, thereby strengthening Esperion's position in the competitive cardiovascular drug market.
- Increased R&D Investment: R&D expenses rose by 26% to $47.9 million in 2025, primarily driven by clinical study costs, demonstrating the company's commitment to innovative drug development, which is expected to lay the groundwork for future product line expansions.
See More
Esperion Reports Q4 Earnings Beat with Strong Revenue Growth
- Significant Revenue Growth: Esperion's Q4 revenue reached $168.45 million, reflecting a remarkable 143.7% year-over-year increase, surpassing expectations by $2.33 million, indicating strong market performance, particularly in new product sales.
- Net Product Sales Surge: U.S. net product sales grew approximately 38% year-over-year to $43.7 million, with full-year 2025 sales also increasing by 38% to $159.6 million, demonstrating significant progress in expanding market share.
- Strong Prescription Growth: Q4 retail prescription equivalents showed a 34% year-over-year increase and an 11.3% sequential growth, reflecting rising consumer demand for Esperion's products and further solidifying its market position.
- Transparent Expense Outlook: The company expects operating expenses for 2026 to range between $225 million and $255 million, including approximately $15 million in non-cash expenses related to stock compensation, indicating a cautious approach to cost management.
See More
Esperion Acquires Corstasis to Expand Product Line
- Acquisition Agreement Details: Esperion Therapeutics has entered into a definitive agreement to acquire Corstasis Therapeutics, which includes a $75 million upfront cash payment and potential royalties and milestone payments totaling up to $180 million, indicating a proactive approach to expanding its product portfolio.
- Market Opportunity Analysis: The acquisition aims to leverage Esperion's established cardiovascular commercial infrastructure, targeting a market opportunity exceeding $4 billion in the U.S., and is expected to drive double-digit revenue growth, enhancing its leadership position in cardiovascular care.
- Financial Structure and Financing: Esperion plans to finance the acquisition through its existing credit facilities and royalty monetization of its Japanese royalties managed by Athyrium Capital Management and HealthCare Royalty, demonstrating flexibility and foresight in its financial operations.
- Stock Performance and Analyst Outlook: Following the acquisition announcement, Esperion's stock fell 5.4% in premarket trading to $3.09, reflecting market caution regarding the deal, while analysts maintain an optimistic outlook on future earnings expectations.
See More
Esperion Acquires Corstasis for $75M to Enhance Cardiovascular Treatment
- Acquisition Overview: Esperion has agreed to acquire all outstanding shares of Corstasis Therapeutics for an upfront payment of $75 million, with the transaction expected to close in Q2 2026, subject to customary closing conditions, indicating Esperion's intent to expand in the biopharmaceutical sector.
- Product Integration Potential: Corstasis's lead product, Enbumyst, received FDA approval in September 2025 as the first nasal diuretic for treating edema associated with congestive heart failure and liver and kidney diseases, and Esperion plans to integrate it into its existing commercial platform to drive sustained double-digit growth.
- Strategic Importance: CEO Sheldon Koenig emphasized that this acquisition not only accelerates the company's momentum but also strengthens its leadership in cardiovascular care, creating lasting value for patients, providers, and shareholders alike.
- Potential Earnings: Under the agreement, Corstasis shareholders are eligible for up to an additional $180 million upon achieving certain regulatory and commercial milestones, along with low double-digit royalties on sales of Enbumyst and follow-on products, enhancing the attractiveness of the deal.
See More
Esperion Therapeutics Set to Announce Q4 Earnings on March 10
- Earnings Announcement: Esperion Therapeutics is set to release its Q4 earnings on March 10 before market open, with a consensus EPS estimate of $0.28, reflecting a substantial year-over-year increase of 354.5%, indicating a significant improvement in profitability that could positively impact stock prices.
- Strong Revenue Expectations: The anticipated revenue for Q4 is $166.12 million, representing a 140.4% year-over-year growth, which highlights the company's enhanced competitiveness in the market and may attract increased investor interest.
- Historical Performance Review: Over the past year, Esperion has exceeded EPS estimates 75% of the time and revenue estimates 100% of the time, demonstrating a consistent performance that bolsters market confidence in its future financial health.
- M&A Activity: Esperion plans to acquire Corstasis for an upfront payment of $75 million, a strategic move that not only expands its product line but also has the potential to enhance market share through resource integration, further solidifying its position in the biopharmaceutical sector.
See More
Esperion Reports Record Q4 2025 Earnings and Strategic Acquisition
- Strong Financial Performance: Esperion's Q4 total revenue reached $168.4 million, marking a 144% year-over-year increase, with U.S. net product revenue at $43.7 million, reflecting approximately a 38% growth compared to the same period in 2024, showcasing robust market execution and product demand.
- Strategic Acquisition Progress: The announced acquisition of Corstasis Therapeutics is expected to create powerful synergies for its global bempedoic acid portfolio and Enbumyst product line, targeting a $4 billion U.S. outpatient heart failure market, thereby further solidifying its market position.
- Accelerated International Expansion: Daiichi Sankyo Europe reported a 51% increase in royalty revenue in Q4, successfully entering 30 countries and launching in France, indicating the company's capability and growth potential in global markets.
- Optimistic Future Outlook: The company projects 2026 operating expenses to range between $225 million and $255 million, including $15 million in non-cash stock compensation expenses, with management expressing confidence in future market positioning and product launches, particularly in the upcoming U.S. dyslipidemia guidelines.
See More
Esperion Reports 21% Revenue Growth in FY25, Acquires Corstasis Therapeutics
- Strong Financial Performance: Esperion reported total revenue of $403.1 million for FY25, reflecting a 21% year-over-year increase, with U.S. net product revenue reaching $159.6 million, up 38%, indicating robust growth in its cardiovascular franchise.
- Strategic Acquisition: The company announced the acquisition of Corstasis Therapeutics to accelerate growth and expand its cardiovascular portfolio, particularly with Enbumyst™ nasal diuretic, which targets a market of over 6.7 million U.S. heart failure patients, enhancing market share.
- Prescription Growth: In Q4 2025, retail prescription equivalents grew by 34% year-over-year and 11.3% quarter-over-quarter, reflecting ongoing improvements in market penetration and brand recognition, thereby strengthening Esperion's position in the competitive cardiovascular drug market.
- Increased R&D Investment: R&D expenses rose by 26% to $47.9 million in 2025, primarily driven by clinical study costs, demonstrating the company's commitment to innovative drug development, which is expected to lay the groundwork for future product line expansions.
See More
Esperion Reports Q4 Earnings Beat with Strong Revenue Growth
- Significant Revenue Growth: Esperion's Q4 revenue reached $168.45 million, reflecting a remarkable 143.7% year-over-year increase, surpassing expectations by $2.33 million, indicating strong market performance, particularly in new product sales.
- Net Product Sales Surge: U.S. net product sales grew approximately 38% year-over-year to $43.7 million, with full-year 2025 sales also increasing by 38% to $159.6 million, demonstrating significant progress in expanding market share.
- Strong Prescription Growth: Q4 retail prescription equivalents showed a 34% year-over-year increase and an 11.3% sequential growth, reflecting rising consumer demand for Esperion's products and further solidifying its market position.
- Transparent Expense Outlook: The company expects operating expenses for 2026 to range between $225 million and $255 million, including approximately $15 million in non-cash expenses related to stock compensation, indicating a cautious approach to cost management.
See More
Esperion Acquires Corstasis to Expand Product Line
- Acquisition Agreement Details: Esperion Therapeutics has entered into a definitive agreement to acquire Corstasis Therapeutics, which includes a $75 million upfront cash payment and potential royalties and milestone payments totaling up to $180 million, indicating a proactive approach to expanding its product portfolio.
- Market Opportunity Analysis: The acquisition aims to leverage Esperion's established cardiovascular commercial infrastructure, targeting a market opportunity exceeding $4 billion in the U.S., and is expected to drive double-digit revenue growth, enhancing its leadership position in cardiovascular care.
- Financial Structure and Financing: Esperion plans to finance the acquisition through its existing credit facilities and royalty monetization of its Japanese royalties managed by Athyrium Capital Management and HealthCare Royalty, demonstrating flexibility and foresight in its financial operations.
- Stock Performance and Analyst Outlook: Following the acquisition announcement, Esperion's stock fell 5.4% in premarket trading to $3.09, reflecting market caution regarding the deal, while analysts maintain an optimistic outlook on future earnings expectations.
See More
Esperion Acquires Corstasis for $75M to Enhance Cardiovascular Treatment
- Acquisition Overview: Esperion has agreed to acquire all outstanding shares of Corstasis Therapeutics for an upfront payment of $75 million, with the transaction expected to close in Q2 2026, subject to customary closing conditions, indicating Esperion's intent to expand in the biopharmaceutical sector.
- Product Integration Potential: Corstasis's lead product, Enbumyst, received FDA approval in September 2025 as the first nasal diuretic for treating edema associated with congestive heart failure and liver and kidney diseases, and Esperion plans to integrate it into its existing commercial platform to drive sustained double-digit growth.
- Strategic Importance: CEO Sheldon Koenig emphasized that this acquisition not only accelerates the company's momentum but also strengthens its leadership in cardiovascular care, creating lasting value for patients, providers, and shareholders alike.
- Potential Earnings: Under the agreement, Corstasis shareholders are eligible for up to an additional $180 million upon achieving certain regulatory and commercial milestones, along with low double-digit royalties on sales of Enbumyst and follow-on products, enhancing the attractiveness of the deal.
See More
